MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation...

Area of Science:

• Hepatology
• Molecular Biology
• Oncology

Background:

• Non-alcoholic fatty liver disease (NAFLD) is a significant risk factor for hepatocellular carcinoma (HCC).
• The precise mechanistic links between NAFLD and HCC remain largely undefined.
• Understanding these pathways is crucial for developing effective therapeutic strategies.

Purpose of the Study:

• To investigate the role of microRNA-21 (miR-21) in the development of NAFLD.
• To explore the potential involvement of miR-21 in the pathogenesis of HCC.
• To elucidate the molecular mechanisms underlying miR-21's function in liver disease and cancer.

Main Methods:

• Utilized a high-fat diet (HFD) mouse model with microRNA-21-anti-sense oligonucleotide (ASO) treatment.
• Employed human hepatoma HepG2 cells treated with oleate to study lipogenesis.
• Assessed miR-21's role in carcinogenesis using soft-agar assays, cell cycle analysis, and xenograft tumor models.

Main Results:

• Increased miR-21 expression was observed in HFD-fed mice and fatty acid-treated HepG2 cells.
• Knockdown of miR-21 reduced hepatic lipid accumulation and inhibited tumor growth in vivo.
• Identified Hbp1 as a novel miR-21 target, which activates p53, a suppressor of lipogenesis and cell proliferation.

Conclusions:

• MicroRNA-21 promotes hepatic lipid accumulation and cancer progression via the Hbp1-p53-Srebp1c pathway.
• This study reveals a novel mechanism linking NAFLD and HCC pathogenesis.
• MicroRNA-21-ASO emerges as a potential therapeutic agent for both NAFLD and HCC.